glucagon receptor

Glucagon receptor antagonist -1 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonist -2 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonist -3 is a highly effective glucagon receptor antagonist.

Glucagon receptor antagonists-5 is an orally bioavailable indazole-based glucagon receptor antagonist (Ki: 32 nM). It has potential for the treatment of type 2 diabetes mellitus (T2DM).

Glucagon receptor antagonist-10 (Compound 11) is a glucagon receptor antagonist with a pIC50 value of 7.154. It is employed in the study of glucose homeostasis.

Glucagon receptor antagonist-11 (Compound 14) is a glucagon receptor antagonist with a pIC50 value of 6.677. This compound, along with Glucagon receptor antagonist-10, is applicable in glucose homeostasis research.

Glucagon receptor antagonist-9 (compound 13) is a potent inhibitor of the glucagon receptor, with a pIC50 of 7.000.

Glucagon Receptor Antagonist Inactive Control is a Glucagon receptor antagonist that can be used in related research in the field of life sciences. Its product number is T36580 and CAS number is 362482-00-6.

Glucagon receptor antagonist I is a competitive antagonist of the glucagon receptor (GCGR; IC50 = 181 nM). It blocks glucagon-induced glycogenolysis in primary human hepatocytes and isolated liver. Glucagon receptor antagonist I, at 50 mg/kg, reduces the increase in glucose levels observed after intraperitoneal administration of glucagon in humanized mice. Glucagon receptor antagonist inactive control does not prevent glucagon-mediated actions.

Orforglipron (LY3502970) belongs to non-peptide small molecule GLP-1 receptor agonists and is a highly selective, orally effective GLP-1 receptor agonist with good cell permeability and oral bioavailability. This compound is used in research on type 2 diabetes and obesity, demonstrating significant glucose-lowering and weight-reducing activities.

Semaglutide TFA is a glucagon-like peptide-1 congener that induces weight loss, lowers blood glucose levels, and reduces cardiovascular risk in diabetic patients.Semaglutide TFA induces mild-to-moderate and transient gastrointestinal disturbances, and may be used in the study of type 2 diabetes and obesity.

Semaglutide is a long-acting, selective, competitive GLP-1R agonist and a long-acting analog of human glucagon-like peptide-1, exhibiting potent hypoglycemic, weight-loss, cardioprotective, and neuroprotective effects. Upon activation of the GLP-1R, semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, while also enhancing autophagy and suppressing oxidative stress and apoptosis. Semaglutide also plays a role in regulating mitochondrial function and lipid metabolism. Semaglutide is being investigated for use in type 2 diabetes, obesity, Parkinson’s disease, metabolic and fatty liver diseases (MASLD), and other neurodegenerative and liver diseases, as well as in cancer research.

Semaglutide Acetate is a GLP-1R agonist (EC50=6.2 pM) with long-acting, selective, competitive, and oral efficacy. Semaglutide acetate can be used in the study of type 2 diabetes.

GLP-1R Agonist DMB is an agonist of glucagon-like peptide 1 receptor (GLP-1R; KB = 26.3 nM for the recombinant human receptor).

Exendin-4 (Exenatide) is a glucagon-like peptide-1 receptor (GLP-1) agonist (IC50: 3.22 nM). Exenatide is a 39 amino acid peptide. Compared to GLP-1, exenatide has a longer half-life of 2.4 hours.

LSN3318839 is a small-molecule compound and a positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), featuring oral activity and selective enhancement of G protein-coupled signaling, which promotes glucose-dependent insulin secretion for blood glucose reduction.

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

Retatrutide is a triple receptor agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), with FDA approval for the indication of obesity.Retatrutide may be used in studies of obesity, type 2 diabetes, and non-alcoholic steatohepatitis.

Tirzepatide (LY-3298176) is a dual agonist of glucose-dependent polypeptide (GIP) (EC50=0.042 nM) and glucagon-like peptide-1 (GLP-1) (EC50=0.086 nM) receptors, and it has neuroprotective activity. It can improve blood pressure and lower low-density lipoprotein (LDL) cholesterol and triglycerides, and can be used to study diabetes and obesity.

Tirzepatide (LY3298176) Acetate (2023788-19-2 free base) is a new molecule that can control blood glucose levels by combining dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[3]

Tirzepatide sodium salt (LY3298176 sodium salt) is a GIP and GLP-1 receptor agonist with neuroprotective activity and can be used to treat obesity.

Avexitide (Exendin-3(9-39)amide) is a specific, competitive GLP-1 receptor antagonist (Ki = 0.36 nM). Avexitide binds to the GLP-1 receptor (GLP-1R) with high affinity (Kd = 0.42 nM), blocking the interaction between endogenous GLP-1 and the receptor, thereby counteracting the effects of excessive GLP-1 secretion. Avexitide is being studied for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism.

Aleniglipron (GSBR-1290) is an orally active, non-peptide GLP-1 agonist that binds to deep orthosteric pockets within transmembrane domains (TM1, TM2, and TM7). It reduces body weight and improves insulin sensitivity, making it suitable for obesity research.

LGD-6972 is an antagonist of glucagon receptor.